Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Apr 28:8:234.
doi: 10.3389/fphar.2017.00234. eCollection 2017.

Management of Benign Prostatic Hyperplasia: Could Dietary Polyphenols Be an Alternative to Existing Therapies?

Affiliations
Review

Management of Benign Prostatic Hyperplasia: Could Dietary Polyphenols Be an Alternative to Existing Therapies?

Chinedum Eleazu et al. Front Pharmacol. .

Abstract

The incidence of benign prostatic hyperplasia (BPH) is gradually on the increase. While conventional drugs such as the α1-adrenergic receptor antagonists and 5α-reductase inhibitors have been found to be useful in the treatment of BPH, the adverse side effects associated with their usage, have led to increased search for alternative means of managing this disease. Furthermore, although surgery has also been suggested to be a sure method, the cost and risks associated with it excludes it as a routine treatment. Dietary polyphenols have gained public interest in recent times due to their roles in the prevention of various diseases that implicate free radicals/reactive oxygen species. However, their roles in the management of BPH have not been explored. Hence, this review on their prospects in the management of BPH and their mechanisms of action. Literature search was carried out in several electronic data bases such as PubMed, Google Scholar, Medline, Agora, and Hinari from1970 to 2017 to identify the current status of knowledge on this concept. The findings from these data bases suggest that while dietary polyphenols may not replace the need for the existing therapies in the management of BPH, they hold promise in BPH management which could be explored by researchers working in this field.

Keywords: antioxidants; benign prostatic hyperplasia; nutraceuticals; nutrition; polyphenols.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
(A) Structures of the polyphenols with 5α-reductase inhibitory actions. (B) Structures of polyphenols with BPH suppressing actions in preclinical studies.

References

    1. Abd E. M. M., Marks J., Kuhnle G., Moore K., Debnam E., Srai S. K., et al. (2006). Absorption, tissue distribution and excretion of pelargonidin and its metabolites following oral administration to rats. Br. J. Nutr. 95 51–58. 10.1079/BJN20051596 - DOI - PubMed
    1. Alberto B., Umberto C., Nazareno S., Andrea G., Andrea S., Marco B., et al. (2009). Benign prostatic hyperplasia and its aetiologies. Eur. Urol. Suppl. 8 865–871. 10.1016/j.eursup.2009.11.002 - DOI
    1. Aleksandra R., Iwona R., Tomasz M., Marcin S., Barbara D., Anna L., et al. (2015). Metabolic syndrome and benign prostatic hyperplasia: association or coincidence? Diabetol. Metab. Syndr. 7:94 10.1186/s13098-015-0089-1 - DOI - PMC - PubMed
    1. Aline B., Alain R., Myriam D., Jean A., Marian D., Mohamed B., et al. (2005). Activation of Caspases-3, -6, and -9 during finasteride treatment of benign prostatic hyperplasia. J. Clin. Endocrinol. Metab. 90 17–25. 10.1210/jc.2004-0712 - DOI - PubMed
    1. Altavilla D., Minutoli L., Polito F., Irrera N., Arena S., Magno C., et al. (2012). Effects of flavocoxid, a dual inhibitor of COX and 5-lipoxygenase enzymes, on benign prostatic hyperplasia. Br. J. Pharmacol. 167 95–108. 10.1111/j.1476-5381.2012.01969.x - DOI - PMC - PubMed

LinkOut - more resources